No Data
No Data
Zhejiang Int'l Group (000411.SZ): As of July 10, the number of company shareholders is 26,095.
Zhejiang Int'l Group (000411.SZ) stated on the investor interaction platform on July 12th that as of July 10th, 2024, the number of shareholders of the company was 26,095.
Zhejiang Int'l Group (000411.SZ): The overall collection period of accounts receivable is currently stable.
Zhejiang Int'l Group (000411.SZ) stated in its investor relations event on July 9th that the overall accounts receivable collection cycle is stable, and the accounts receivable collection cycle in different regions of Zhejiang Province varies, as do the collection cycles for different types of customers. The company values the management of related indicators such as accounts receivable turnover and has established a credit risk management system that covers the entire business process both before, during, and after transactions.
Zhejiang Int'l Group (000411.SZ): At present, the proportion of the company's cross-border e-commerce business to revenue is extremely small.
Zhejiang Int'l Group (000411.SZ) stated on the investor communication platform that the company has established Zhejiang Int'l Pharmaceutical Industry Cross-border e-commerce business in the field of medical and health industries. Currently, cross-border e-commerce business accounts for a very small proportion of the company's revenue.
Zhejiang Int'l Group (000411.SZ) has business collaborations with large pharmaceutical companies including Eli Lilly and Co, Novo-Nordisk A/S.
Zhejiang Int'l Group (000411.SZ) stated on the investor interaction platform on June 27th that the company is a pharmaceutical distribution enterprise mainly engaged in the wholesale and retail business of pharmaceuticals and medical instruments, and has business cooperation with large pharmaceutical enterprises including Eli Lilly and Co and Novo-Nordisk A/S. At present, the company operates tens of thousands of varieties and specifications of pharmaceutical products, including hypoglycemic products, but the sales of specific single variety and specification account for a small proportion of the company's overall sales. The company will continue to pay attention to newly launched drugs and actively carry out relevant introduction work.
As of June 20, 2024, the number of shareholders of Zhejiang Int'l Group (000411.SZ) was 26526.
Zhejiang Int'l Group (000411.SZ) stated on the investor platform on June 27 that as of June 20, 2024, the company had 26,526 shareholders.
Zhejiang Int'l Group (000411.SZ): Int'l Logistics plans to sign a framework agreement with the Grand Canal Commission.
On June 5th, the Zhejiang Int'l Group (000411.SZ) announced that its subsidiary, Zhejiang Int'l Logistics Co., Ltd. (referred to as "Int'l Logistics"), owns a land parcel at No. 7 Kangle Road, Gongshu District, Hangzhou (referred to as the "Kangle Road Parcel", i.e. "Parcel 2" in the main content of the contract). In order to support its operations, Int'l Logistics intends to sign a framework agreement with the Hangzhou Deyunhe Smart Future City Management Committee (referred to as the "Deyunhe Committee") in the near future. The two parties have reached an agreement on the following matters: the Deyunhe Committee will support the company in lawfully and compliantly participating in the public bidding process for the target land parcel in Gongshu District, Hangzhou ("
No Data